Suppr超能文献

肠道微生物群、高血压和慢性肾脏病:最新进展。

Gut microbiota, hypertension and chronic kidney disease: Recent advances.

机构信息

Unità Operativa di Cardiologia, Azienda Ospedaliero Universitaria, Sassari, Italy; Department of Medical Sciences, San Giovanni Battista Hospital, Turin, Italy.

HUMANITAS Gradenigo, University of Turin, Turin, Italy; Department of Medical Sciences, San Giovanni Battista Hospital, Turin, Italy.

出版信息

Pharmacol Res. 2019 Jun;144:390-408. doi: 10.1016/j.phrs.2018.01.013. Epub 2018 Jan 31.

Abstract

A large number of different microbial species populates intestine. Extensive research has studied the entire microbial population and their genes (microbiome) by using metagenomics, metatranscriptomics and metabolomic analysis. Studies suggest that the imbalances of the microbial community causes alterations in the intestinal homeostasis, leading to repercussions on other systems: metabolic, nervous, cardiovascular, immune. These studies have also shown that alterations in the structure and function of the gut microbiota play a key role in the pathogenesis and complications of Hypertension (HTN) and Chronic Kidney Disease (CKD). Increased blood pressure (BP) and CKD are two leading risk factors for cardiovascular disease and their treatment represents a challenge for the clinicians. In this Review, we discuss mechanisms whereby gut microbiota (GM) and its metabolites act on downstream cellular targets to contribute to the pathogenesis of HTN and CKD, and potential therapeutic implications.

摘要

大量不同的微生物物种栖息在肠道中。通过宏基因组学、宏转录组学和代谢组学分析,广泛的研究已经研究了整个微生物种群及其基因(微生物组)。研究表明,微生物群落的失衡会导致肠道内稳态的改变,从而对其他系统产生影响:代谢、神经、心血管、免疫。这些研究还表明,肠道微生物群的结构和功能的改变在高血压(HTN)和慢性肾脏病(CKD)的发病机制和并发症中起着关键作用。血压升高(BP)和 CKD 是心血管疾病的两个主要危险因素,其治疗对临床医生来说是一个挑战。在这篇综述中,我们讨论了肠道微生物群(GM)及其代谢物作用于下游细胞靶点的机制,这些机制有助于高血压和慢性肾脏病的发病机制,以及潜在的治疗意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验